Pleuropulmonary Toxicity of Another Anti-Parkinson`s Drug: Cabergoline
نویسندگان
چکیده
منابع مشابه
Pleuropulmonary Toxicity of Another Anti-Parkinson’s Drug: Cabergoline
Many drugs may cause toxic injury to the lungs and the pleura. Cabergoline is an ergoline derivative which has been used in Spain for seven years to control symptoms of Parkinson's disease. We report a patient with dyspnea, bilateral pleural effusion and distal swelling. After a series of complementary tests (blood analysis, chest CT, echocardiogram, pleural tap, pleural biopsy), etiological sc...
متن کامل[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug].
We report a case of pleural effusion, pericardial thickening, and pulmonary involvement in a patient with dry cough, dyspnea, edema, and changes in the skin of the lower limbs. Treatment with cabergoline (Sogilen) had been started 4 months earlier. Pleural effusion, pericardial thickening, and impaired pulmonary function (airflow obstruction, increased airway resistance, and reduced carbon mono...
متن کاملNon-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinsons Disease
Background: Experimental evidence supports a preventative role for non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease (PD). Methods: We investigated associations between use of aspirin, nonaspirin NSAIDs, and acetaminophen and PD in a large population-based casecontrol study using Danish health and pharmacy registries. We identified 1,931 PD cases reported in hospital or outp...
متن کاملNon-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinsons Disease
Background: Experimental evidence supports a preventative role for non-steroidal anti-inflammatory drugs (NSAIDs) in Parkinson’s disease (PD). Methods: We investigated associations between use of aspirin, nonaspirin NSAIDs, and acetaminophen and PD in a large population-based casecontrol study using Danish health and pharmacy registries. We identified 1,931 PD cases reported in hospital or outp...
متن کاملPleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Open Respiratory Medicine Journal
سال: 2009
ISSN: 1874-3064
DOI: 10.2174/1874306400903010090